



## ANNALS OF MULTIDISCIPLINARY RESEARCH, INNOVATION AND TECHNOLOGY (AMRIT)

(A peer-reviewed open access multidisciplinary journal)

www.adtu.in/amrit



### REVIEW ARTICLE

## Traditional Nutraceuticals and Its Impact in the Avoidance of Different Type of Cardiovascular Diseases (CVD)

Subhadip Bera<sup>1</sup>, Bapi Ray Sarkar<sup>1</sup>, Prosanta Pal<sup>1\*</sup>

<sup>1</sup>Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, West Bengal, India

\*Corresponding author: Prosanta Pal *Email: prosanta\_pal@rediffmail.com*

Article Chronicle: Received: 7/8/2021 Accepted: 23/12/2021 Published Online: 12/01/2022

### Abstract

Nutraceuticals are natural compounds with nutritional value that act efficaciously in the presentation and treatment of diseases. Traditional nutraceuticals are referred to as naturally occurring whole foods with potential health benefits. Several classes of nutraceuticals have been proposed to have potential benefits in the treatment of cardiovascular diseases (CVD), and the ones with the strongest evidence are summarized in this review. Several foods and dietary supplements have been shown to protect against developing CVD which are reported to be used worldwide. Dietary variables are significant supporters of cardiovascular danger, either straightforwardly, or through their impacts on other cardiovascular ailments including hypertension, dyslipidemia and diabetes mellitus. Nutraceuticals are normal dietary mixtures, which have been demonstrated to be useful in deterrent medication or the treatment of sickness. A few food varieties and dietary enhancements have been shown to secure against the improvement of CVD. The point of this audit is to introduce a report on the latest proof identifying the utilization of nutraceuticals regarding the avoidance and treatment of CVD.

**Keywords:** *Traditional nutraceutical, Cardiovascular disease (CVD), Lycopene, Curcumin, Hypertension*

### 1. Introduction

The expression "nutraceuticals" was presented by Stephen DeFelice, organizer, and executive of the Establishment for Development in Medication, in 1989. A nutraceutical is characterized as a "food, or portions of a food, that give clinical or medical advantages, including the avoidance and therapy of illness (1). The Cardiovascular disease (CVD) is normal, without a doubt most of grown-ups over sixty years old will encounter some indication of CVD. In view of information from 2012 and 2013, it has been assessed that CVD is answerable for 17.3 million passing every year around the world (2). Hazard factors for CVD can be sorted as modifiable and non-modifiable. Modifiable danger factors incorporate weight, hypertension, hyperlipidemia, diabetes mellitus, metabolic condition and way of life hazard factors like undesirable eating routine, smoking and actual inertia. Dietary variables are likewise significant supporters of cardiovascular danger, either straightforwardly, or through their impacts on other danger factors including hypertension, dyslipidemia and diabetes mellitus (3).

Decrease of hazard factors in the populace, particularly circulatory strain decrease and lipid-bringing down can have significant effects upon mortality from CVD(4). Defensive impacts against CVD have been shown for a few food varieties and dietary enhancements (5). Accordingly introducing additional opportunities for populace level decrease of CVD hazard. Proof recommends that this methodology is extremely encouraging. For instance, in the PREDIMED observational investigation, members in the most noteworthy quintile of polyphenol utilization had a general danger of CVD of 54% contrasted with those in the least quintile (6). The point of this survey is to introduce a report on the latest proof identifying with the utilization of nutraceuticals with regards to the anticipation and treatment of CVD. Lamentably, not many investigations have estimated the relationship between nutraceutical utilizations and "hard" results like mortality. Enormous randomized controlled preliminaries are especially uncommon, and subsequently there is a lack of proof around here. Along these lines, our conversation will be generally centered on the impacts of nu-

traceuticals on very much described danger factors for CVD (6; 7).

## 2. Different Nutraceuticals Used In CVD

### 2.1 Garlic

Garlic (*Allium sativum*) has assumed a generous noteworthy part in both food and therapeutic significance (7). Garlic is for the most part made of water (65%), and carbs such as fructose, sulfur mixtures, proteins and free amino acids (8). The sulfur intensifies present or created from garlic are responsible for their dietary and therapeutic capacities (9). It has as of late been established that piece of the cardiovascular advantages of garlic is because of the presence of allicin, otherwise called diallyl thiosulfinate (10). At the point when the cell construction of garlic is harmed, C-S-lyase (alliinase) follows up on alliin (S-allyl-L-Cysteine sulfoxide) and changes over it into allicin (allylthiosulfinate). Allicin structures a few sulfides by non-enzymatic response as diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide (DATS), or methyl allyl trisulfide (MATs), all of which act with strong antiplatelet movement (11). Garlic admission can hinder platelet conglomeration in humans (12), improves vasodilatation and fibrinolysis in creatures and people (13). A significant and all-around contemplated garlic arrangement is matured garlic remove (AGE), which is ready by putting away cut crude garlic in an ethanol answer for a very long time, at room temperature. Further investigations are needed to survey the advantages of this garlic readiness. To additionally research the properties of AGE, future examinations could look at a mix of cell reinforcements over a more extended span, and analyze a diabetic partner with higher cardiovascular danger, for example, those with set-up heart illness (14). Notwithstanding AGE, there are different arrangements of garlic, for example, garlic oil, garlic powder, and garlic oil, that might introduce helpful results (10; 15). Notwithstanding the before-referenced cardiovascular impacts, garlic was found to act in a cardioprotective way as advanced by H<sub>2</sub>S, which can be delivered by the change of garlic subordinates into human erythrocytes, ensuring the heart by cancer prevention agent, antiapoptotic and mitigating activities. H<sub>2</sub>S is a cardioprotective gas flagging particle and is responsible for a wide scope of physiological jobs in mammalian tissues. It is significant for cell work and ensures the cell against apoptosis, oxidative pressure and putrefaction (16). Treatment with exogenous H<sub>2</sub>S is conceivable and might be responsible for a huge decrease in the size of myocardial localized necrosis in mice with murine sores and ischemia/reperfusion (17). An enormous measure of logical writing upholds the recommendation that garlic utilization has a huge cardioprotective impact (18). A deliberate survey and meta-examination presumed that in hypertensive patients treated with garlic-just arrangements, shown a decrease in in pulse in people with hypertension, when contrasted with fake treatment (19) A new report found that garlic can decrease pulse in hypertensive subjects, like standard circulatory strain drug; for example, angiotensin-changing protein inhibitors, angiotensin II - receptor blockers, calcium-channel blockers, and diuretics (20). Besides, the supplementation with garlic arrangements might be an integral treatment alter-

native for hypertension and tests ought to be performed to explore whether garlic could have an enemy of hypertensive impact, in pre-hypertensive people, which would be significant in the avoidance of hypertension movement (19). In a meta-examination, garlic gave significant outcomes in subjects with gentle hypertension; nonetheless, inadequate proof was accumulated to suggest for clinical treatment (21) and despite investigations pulse and garlic arrangements have been uncertain (22; 23; 24; 25). Further testing should be performed to explain the advantages of garlic in the treatment of hypertension and cardiovascular illness, and although there is solid proof of its helpful heart impacts. Alert ought to be practiced in the utilization of garlic because of the presence of gastrointestinal issues (26). Taken together, the clinical preliminaries propose that garlic assume a part forestalling or postponing cardiovascular infection; yet more examinations are expected to affirm its belongings.

### 2.2 Tomato and lycopene

Lycopene is a carotenoid found in red foods grown from the ground, like papayas, tomatoes, red peppers, watermelon, and others (27). Tomatoes are very much perceived for their culinary adaptability and furthermore add to dietary health benefits (28). Practically 90% of the complete carotenoids that make up the tomato are made of lycopene (29), although it is likewise made of carotene, folate, phenolic mixtures and nutrients C and E (30). The relationship among tomato and lycopene utilization with cardiovascular sickness hazard decrease has acquired exploration interest (28). As per the Framingham Heart Offspring Study, there is a solid reverse relationship between the utilization of lycopene and the occurrence of myocardial localized necrosis, coronary deficiency and angina pectoris (31). Moreover, plasma levels of lycopene in hypertension, intense myocardial dead tissue, stroke, and atherosclerosis were portrayed as low (32; 33). Among the significant carotenoids, lycopene is the most impressive cell reinforcement and assumes a significant part in forestalling cardiovascular illness in people (34). Lycopene bioavailability in supplements has not been as broadly examined and remains a significant region for research (28). A trial study utilizing wistar rodents showed that tomato supplementation for 90 days advanced changes in miRNA articulation and decreased oxidative pressure. What's more, these progressions give off an impression of being responsible for the decrease of the cross-sectional space of left ventricular myocytes and improvement of diastolic capacity. Despite this, further examinations should be led to explore the expected focuses of tomato and lycopene in the avoidance and treatment of cardiovascular infections and to explain their gainful heart impacts, which have not yet been considered (35). It is notable that endothelial capacity reflects vascular wellbeing (CITE). Moreover, endothelial brokenness is engaged with the advancement of atherosclerosis and, also, coronary or fringe vascular endothelium brokenness has all the earmarks of being a free indicator of cardiovascular occasions (36). Expanded oxidative pressure might be a contributing instrument for endothelial brokenness (37). Strangely, in a randomized, twofold visually impaired, placebo controlled study, the 8-week supplementation with lycopene has been

displayed to advance useful impacts of oxidative pressure biomarkers (through the decrease of oxidative DNA harm and expanded plasma superoxide dismutase enzymatic action). Also, their cancer prevention agent impacts might assume a generous part in working on endothelial capacity, which is profoundly identified with incendiary markers. Those outcomes exhibit the advantageous impact of every day lycopene consumption (38). Many examinations have related tomato and lycopene with lower rate paces of cardiovascular illnesses (32; 33; 39), anyway, the impact of lycopene supplementation stays indistinct and unverified (40). Albeit practically 90% of the complete carotenoids that are found in the tomato are made of lycopene (29), the other bioactive mixtures that are found ought to likewise be concentrated to more readily comprehend its advantageous impacts. What's more, until new examination explains and affirms the huge advantages of lycopene supplementation in people, it is prescribed to burn-through foods grown from the ground wealthy in normal carotenoids (40).

### 2.3 Spirulina

Spirulina is a blue-green microalga (Cyanobacterium). Spirulina is a rich wellspring of protein, nutrients, minerals, carotenoids, and phycocyanins and has an extremely long history of utilization as a human food item with no evident worries over wellbeing (41; 42). Spirulina supplementation has been associated with useful modifications to blood lipid profiles (43; 44). Spirulina maxima, given orally (4.5 g/day, for about a month and a half), was related with huge changes in TC and LDL-C focuses (45). Besides, in a populace of people with dyslipidemia, utilization of 1 g Spirulina each day for 12 weeks diminished mean degrees of fatty oils, LDL-C, and TC, with no obvious impact on plasma convergences of HDL-C (46). A new meta-investigation of seven randomized controlled preliminaries with Spirulina seemed to affirm these discoveries (47). Further very well-planned preliminaries are needed to explain the component of activity of Spirulina supplementation in dyslipidemia and to decide its impacts on cardiovascular results.

### 2.4 Curcumin

Curcumin has an impact on the avoidance of cardiovascular hypertrophy and cardiovascular breakdown. Its drawn-out ingestion seems to alter hereditary expression associated with cholesterol homeostasis. It diminishes serum lipid peroxides and absolute serum cholesterol. Further, curcuminoids have a layer settling impact in myocardial ischemia, cardiovascular hypertrophy, and cardiovascular breakdown (48). It very well might be viable in CVD, stroke and cardiovascular breakdown by further developing the declining capacity of the heart and vasculature. The examinations show that curcumin can lessen constant irritation actuated by stoutness and metabolic disorder, alleviate the effect of insulin opposition (IR) and work on their vascular capacity. The IR, metabolic condition and adiposity add to ongoing aggravation, which opens tissues to constant, second rate oxidative pressure, and undermines the uprightness of cell DNA, proteins, and other basic primary and utilitarian particles fundamental for homeostasis (49) A few all-around planned human investigations have recorded curcumin's capacity to battle constant aggravation (50).

Three late investigations affirmed that taking curcumin upgraded with bioperine for further developed bioavailability prompted huge decreases in levels of various incendiary cytokines that intervened in the impact of persistent irritation (51). Another investigation has featured that curcumin supplementation has a lipid adjusting impact (52). It impacts practically the entirety of the pathways by which cholesterol arrives at the circulatory system including retention from diet, expulsion of cholesterol in the liver, transportation of cholesterol out of cells, and expulsion of cholesterol from tissues all through the body. Likewise, it additionally further develops HDL-C (53). Also, curcumin has the capacity to rummage ROS, decreasing the danger of oxidative injury and in this manner incendiary harm. Curcumin constricts rapamycin-instigated cell injury of vascular endothelial cells in creature examines (54) and seems to work on endothelial capacity (55) and hinders advancement of diabetic microangiopathy and cardiomyopathy (56; 57).

### 2.5 Soya

Note that utilization of soy protein doesn't seem to have a hypocholesterolemic impact in grown-ups with low or typical cholesterol levels. Accordingly, there is no requirement for worry that soy could cause perilously low cholesterol levels. In an investigation of 12 grown-ups with a mean absolute cholesterol level of 145 mg/dL at benchmark, the consolidation of 66 to 80 g soy protein (meat supplanted by soy analogs and milk supplanted by soy refreshment) brought about no critical changes in serum lipids (58). Other examiners who contemplated the impact of soy protein as a component of a hypocaloric diet found fundamentally lower aggregate and LDL cholesterol contrasted and a customary hypocaloric diet (59; 60) Sacks et al (61) tracked down no huge change in serum lipids in 13 severe vegans whose gauge cholesterol was 129 mg/dL (62). Tracked down no critical change in 13 normocholesterolemic men 20 to 50 years old (mean gauge absolute cholesterol, 169 mg/dL) who burned-through 50 g soy protein notwithstanding an eating routine low in immersed fat and cholesterol. In the meta-examination of the impact of soy protein on serum cholesterol levels by Anderson et al (63) no critical impact of soy protein was found for those with a cholesterol. Despite the fact that there have been some clashing outcomes in examinations in grown-ups with raised serum cholesterol levels, most investigations report aggregate and LDL cholesterol decreases after the expansion of soy protein to an eating routine that is low in soaked fat and cholesterol. In a new report, postmenopausal ladies on a tight eating routine low in soaked fat and cholesterol (NCEP Step I diet) devoured 40 g/d of soy protein with either 56 or 90 mg of isoflavones every day or casein for a half year. Both soy bunches had fundamentally better blood lipid profiles (normal change from gauge, 8.2% reduction in non-HDL cholesterol and a 4.4% expansion in HDL cholesterol) than the casein bunch. Nonetheless, no distinctions in lipids were seen between the 2 isoflavone levels (63) HDL altogether expanded 7% from benchmark with utilization of 32 g soy protein as soymilk in all kinds of people with hypercholesterolemia (64). Crouse detailed decreases of 4% and 6% altogether and LDL cholesterol, separately, in hypercholesterolemic people burning through 25 g soy protein with isoflavones (see beneath) as

a component of an eating routine low in immersed fat and cholesterol.

## 2.6 Omega 3 fatty acid

As of today, the 3FAs are among the most normally recommended supplements (65). They seem to diminish TG, aggravation and platelet total, cause vasodilatation, and further develop blood rheology, endothelial and myocardial capacity. While most usually utilized for essential and auxiliary counteraction of CVD, they have been attempted in different ailments including gastrointestinal, rheumatic, metabolic, renal, dermatologic, pneumonic and surprisingly mental problems. There have been reported a few atomic and cell impacts of 3FAs. The creatures examined have recorded that adding 3FAs to cell layers works on cell work by connection and adjustment of film channels and changing the physicochemical supportive of parties of cell layer. film-fused 3FAs can change layer protein flagging well. Further, the incorporation of 3FAs into the cell layer has been identified with changes in H-Ras flagging protein and smothered protein kinase C-theta flagging (66). The 3FAs likewise apply calming properties through different instruments. They smother the creation of interleukin-2, the intense stage reactions, and change the creation of eicosanoids, for example, thromboxane A2, leukotriene B4, prompting decreased inflammation. Further, they hinder lipopolysaccharide-prompted aggravation (67). By restricting to explicit atomic receptors and recording factors like PPAR-, HNF-4 and SREBP-1c, they modify quality articulation. These mitigating properties of 3FAs might diminish vascular atherosclerosis. A few examinations, then again, have raised questions on these impacts of 3FAs. In a preliminary of 20 solid competitors, every day, supplementation with 3.6 grams of 3FAs for about a month and a half didn't modify cytokine reactions to exhausting activity nor changed the blood centralization of neutrophils and lymphocytes (68). The 3FAs might work on endothelial capacity by advancing arrival of nitric oxide from endothelial cells (69) and decline resting systolic and diastolic pulse by joining EPA and DHA into layer phospholipids and modifying well the blood vessel consistence. In high dosages, 3FAs increment draining time and have a hostile to thrombotic impact (70), which might be clarified by property of 3FAs to hinder platelets. Further, EPA and DHA lower tissue levels of arachidonic corrosive and supplant it in cell layer with EPA-inferred eicosanoids, which are less vasoconstrictive and have less platelet collecting impacts (71). The 3FAs are processed to thromboxane A3, rather than arachidonic corrosive which is used to thromboxane A2. The thromboxane A3 isn't pretty much as intense as thromboxane A2 in initiating platelets and setting off vasoconstriction. Nonetheless, human preliminaries don't confirm a steady impact on coagulation factors and 442 platelet total, basically in the ordinarily endorsed dosages of 3FAs. 3FAs can restrain myocyte voltage-gated sodium channels and drag out the general unmanageable period, and consequently may impact pulse. The 3FAs decline serum levels of fatty substances by diminishing hepatic amalgamation of extremely low-thickness lipoprotein and speeding up degradation of unsaturated fats and fatty oil freedom from the plasma (72). A few investigations have shown that 3FAs further develop

stream-interceded blood vessel widening and the mechanical capacity of the heart (73). Then again, with respect to their impacts on lipoproteins, randomized controlled preliminaries have shown blended outcomes. Notwithstanding the plenitude of studies concerning omega-3 enhancements, both positive and negative preliminaries, there is no obvious proof about their advantages. An expected test more than quite a while, may have been, tied in with details of positive discoveries by industry and favorable to omega-3 nutritionists/scholastics while underestimating the negative realities. Likewise, these items may not be liberated from incidental effects and dangers. One specific danger for draining and haemorrhagic stroke merit extraordinary consideration (74). In synopsis, in view of the current proof, it very well may be reasoned that omega-3 enhancements may give CV advantages however, their advantages might be negligible (75).

## 3. Conclusion

The beneficial effects of functional foods and Nutraceuticals reduce the risk of cardiovascular diseases along with the reduced risk of many other diseases. Nutraceuticals have been convincingly demonstrated to be beneficial for their intended purpose when consumed as part of a generally well-balanced and healthful diet. Dietary factors, as well as Nutraceuticals are either directly or indirectly contribute towards reducing the cardiovascular risk factors along with diabetes mellitus, hypertension and dyslipidemia. Traditional Nutraceuticals are obtained from nature which comprises various nutritional compounds having therapeutic potential. Dietary supplements and several foods in the form of nutraceuticals have been reported very effective against CVD. This review is made to provide an update on the most recent evidence relating traditional utilization of nutraceuticals in the perspective of the prevention as well as treatment of CVD.

**Conflict of Interest** The authors have no conflicts of interest to declare.

**Acknowledgments** The authors express their gratitude and thanks to the authorities of the University of North Bengal, Darjeeling, W.B., India for providing the required support and motivation to complete the article.

## References

- [1] S. L. DeFelice, "The nutraceutical revolution: its impact on food industry R&D," *Trends in Food Science & Technology*, vol. 6, no. 2, pp. 59-61, 1995, publisher: Elsevier.
- [2] S. Voelter-Mahlknecht, "Epigenetic associations in relation to cardiovascular prevention and therapeutics," *Clinical epigenetics*, vol. 8, no. 1, pp. 1-17, 2016, publisher: Springer.
- [3] M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. L. Catapano, M.-T. Cooney, U. Corrà, B. Cosyns, and C. Deaton, "Guidelines: Editor's choice: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)," *European heart journal*, vol. 37, no. 29, p. 2315, 2016, publisher: Oxford University Press.

- [4] C. O'Keeffe, Z. Kabir, M. O'Flaherty, J. Walton, S. Capewell, and I. J. Perry, "Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland," *BMJ open*, vol. 3, no. 7, p. e002837, 2013, publisher: British Medical Journal Publishing Group.
- [5] E. M. Alissa and G. A. Ferns, "Functional foods and nutraceuticals in the primary prevention of cardiovascular diseases," *Journal of nutrition and metabolism*, vol. 2012, 2012, publisher: Hindawi.
- [6] A. Tresserra-Rimbau and E. Rimm, "Medina-Rem on A, Martinez-Gonzalez MA, de la Torre R, Corella D, et al. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study," *Nutr Metab Cardiovasc Dis*, vol. 24, pp. 639-47, 2014.
- [7] L. D. Lawson, "Garlic: a review of its medicinal effects and indicated active compounds," *Blood*, vol. 179, p. 62, 1998.
- [8] L. Lawson, "The composition and chemistry of garlic cloves and processed garlic," *Garlic: The science and therapeutic applications of Allium sativum L. and related species*, pp. 37-109, 1996, publisher: Williams & Wilkins.
- [9] T. Ariga and T. Seki, "Antithrombotic and anticancer effects of garlic-derived sulfur compounds: A review," *Biofactors*, vol. 26, no. 2, pp. 93-103, 2006, publisher: Wiley Online Library.
- [10] J. M. Bradley, C. L. Organ, and D. J. Lefer, "Garlic-derived organic polysulfides and myocardial protection," *The Journal of nutrition*, vol. 146, no. 2, pp. 403S-409S, 2016, publisher: Oxford University Press.
- [11] T. Ariga, S. Oshiba, and T. Tamada, "Platelet aggregation inhibitor in garlic," *The Lancet*, vol. 317, no. 8212, pp. 150-151, 1981, publisher: Elsevier.
- [12] R. Apitz-Castro, S. Cabrera, M. Cruz, E. Ledezma, and M. Jain, "Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure," *Thrombosis research*, vol. 32, no. 2, pp. 155-169, 1983, publisher: Elsevier.
- [13] G. A. Benavides, G. L. Squadrito, R. W. Mills, H. D. Patel, T. S. Isbell, R. P. Patel, V. M. Darley-Usmar, J. E. Doeller, and D. W. Kraus, "Hydrogen sulfide mediates the vasoactivity of garlic," *Proceedings of the National Academy of Sciences*, vol. 104, no. 46, pp. 17977-17982, 2007, publisher: National Acad Sciences.
- [14] M. Atkin, D. Laight, and M. H. Cummings, "The effects of garlic extract upon endothelial function, vascular inflammation, oxidative stress and insulin resistance in adults with type 2 diabetes at high cardiovascular risk. A pilot double blind randomized placebo controlled trial," *Journal of Diabetes and its Complications*, vol. 30, no. 4, pp. 723-727, 2016, publisher: Elsevier.
- [15] W. Qidwai and T. Ashfaq, "Role of garlic usage in cardiovascular disease prevention: an evidence-based approach," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, 2013, publisher: Hindawi.
- [16] E. Donnarumma, R. K. Trivedi, and D. J. Lefer, "Protective actions of H2S in acute myocardial infarction and heart failure," *Comprehensive Physiology*, vol. 7, no. 2, pp. 583-602, 2011, publisher: John Wiley & Sons, Inc. Hoboken, NJ, USA.
- [17] A. Sivarajah, M. Collino, M. Yasin, E. Benetti, M. Gallicchio, E. Mazzon, S. Cuzzocrea, R. Fantozzi, and C. Thiemermann, "Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R," *Shock*, vol. 31, no. 3, pp. 267-274, 2009, publisher: LWW.
- [18] S. K. Banerjee and S. K. Maulik, "Effect of garlic on cardiovascular disorders: a review," *Nutrition journal*, vol. 1, no. 1, pp. 1-14, 2002, publisher: BioMed Central.
- [19] K. Ried, O. R. Frank, N. P. Stocks, P. Fakler, and T. Sullivan, "Effect of garlic on blood pressure: a systematic review and meta-analysis," *BMC cardiovascular disorders*, vol. 8, no. 1, pp. 1-12, 2008, publisher: Springer.
- [20] K. Ried and P. Fakler, "Potential of garlic (*Allium sativum*) in lowering high blood pressure: mechanisms of action and clinical relevance," *Integrated blood pressure control*, vol. 7, p. 71, 2014, publisher: Dove Press.
- [21] C. A. Silagy and H. Neil, "A meta-analysis of the effect of garlic on blood pressure," *Journal of hypertension*, vol. 12, no. 4, pp. 463-468, 1994.
- [22] K. Rahman and G. M. Lowe, "Garlic and cardiovascular disease: a critical review," *The Journal of nutrition*, vol. 136, no. 3, pp. 736S-740S, 2006, publisher: Oxford University Press.
- [23] Q. T. Edwards, S. Colquist, and A. Maradiegue, "What's cooking with garlic: is this complementary and alternative medicine for hypertension?" *Journal of the American Academy of Nurse Practitioners*, vol. 17, no. 9, pp. 381-385, 2005, publisher: Wiley Online Library.
- [24] B. Turner, C. Mølgaard, and P. Marckmann, "Effect of garlic (*Allium sativum*) powder tablets on serum lipids, blood pressure and arterial stiffness in normo-lipidaemic volunteers: a randomised, double-blind, placebo-controlled trial," *British journal of nutrition*, vol. 92, no. 4, pp. 701-706, 2004, publisher: Cambridge University Press.
- [25] M. H. Pittler and E. Ernst, "Clinical effectiveness of garlic (*Allium sativum*)," *Molecular nutrition & food research*, vol. 51, no. 11, pp. 1382-1385, 2007, publisher: Wiley Online Library.
- [26] T. Hoshino, N. Kashimoto, and S. Kasuga, "Effects of garlic preparations on the gastrointestinal mucosa," *The Journal of nutrition*, vol. 131, no. 3, pp. 1109S-1113S, 2001, publisher: Oxford University Press.
- [27] C. B. RM, "Functional properties and health benefits of lycopene," *Nutricion hospitalaria*, vol. 28, no. 1, pp. 6-15, 2013.
- [28] B. M. Burton-Freeman and H. D. Sesso, "Whole food versus supplement: comparing the clinical evidence of tomato intake and lycopene supplementation on cardiovascular risk factors," *Advances in Nutrition*, vol. 5, no. 5, pp. 457-485, 2014, publisher: Oxford University Press.
- [29] Y.-M. Hsu, C.-H. Lai, C.-Y. Chang, C.-T. Fan, C.-T. Chen, and C.-H. Wu, "Characterizing the lipid-lowering effects and antioxidant mechanisms of tomato paste," *Bioscience, biotechnology, and biochemistry*, vol. 72, no. 3, pp. 677-685, 2008, publisher: Japan Society for Bioscience, Biotechnology, and Agrochemistry.
- [30] A. Raiola, M. M. Rigano, R. Calafiore, L. Frusciante, and A. Barone, "Enhancing the health-promoting effects of tomato fruit for biofortified food," *Mediators of inflammation*, vol. 2014, 2014, publisher: Hindawi.
- [31] P. F. Jacques, A. Lyass, J. M. Massaro, R. S. Vasan, and R. B. D'Agostino Sr, "Relationship of lycopene intake and consumption of tomato products to incident CVD," *British Journal of Nutrition*, vol. 110, no. 3, pp. 545-551, 2013, publisher: Cambridge University Press.
- [32] T. Wolak and E. Paran, "Can carotenoids attenuate vascular aging?" *Vascular pharmacology*, vol. 59, no. 3-4, pp. 63-66, 2013, publisher: Elsevier.
- [33] G. Riccioni, N. D'Orazio, N. Palumbo, V. Bucciarelli, E. di Ilio, L. A. Bazzano, and T. Bucciarelli, "Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease In Manfredonia Study," *European Journal of Preventive Cardiology*, vol. 16, no. 3, pp. 351-357, 2009, publisher: Oxford University Press.
- [34] S. Agarwal and A. V. Rao, "Tomato lycopene and its role in human health and chronic diseases," *Cmaj*, vol. 163, no. 6, pp. 739-744, 2000, publisher: Can Med Assoc.
- [35] B. L. Pereira, F. C. Arruda, P. P. Reis, T. F. Felix, P. P. Santos, B. P. Rafacho, A. F. Gonçalves, R. T. Claro, P. S. Azevedo, and B. F. Polegato, "Tomato (*Lycopersicon esculentum*) supplementation induces changes in cardiac miRNA expression, reduces oxidative stress and left ventricular mass, and improves diastolic function," *Nutrients*, vol. 7, no. 11, pp. 9640-9649, 2015, publisher: Multidisciplinary Digital Publishing Institute.

- [36] P. O. Bonetti, L. O. Lerman, and A. Lerman, "Endothelial dysfunction: a marker of atherosclerotic risk," *Arteriosclerosis, thrombosis, and vascular biology*, vol. 23, no. 2, pp. 168–175, 2003, publisher: Am Heart Assoc.
- [37] M. E. Widlansky, N. Gokce, J. F. Keane, and J. A. Vita, "The clinical implications of endothelial dysfunction," *Journal of the American College of Cardiology*, vol. 42, no. 7, pp. 1149–1160, 2003, publisher: American College of Cardiology Foundation Washington, DC.
- [38] J. Y. Kim, J. K. Paik, O. Y. Kim, H. W. Park, J. H. Lee, Y. Jang, and J. H. Lee, "Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men," *Atherosclerosis*, vol. 215, no. 1, pp. 189–195, 2011, publisher: Elsevier.
- [39] J. K. Willcox, G. L. Catignani, and S. Lazarus, "Tomatoes and cardiovascular health," 2003, publisher: Taylor & Francis.
- [40] J. Chen, Y. Song, and L. Zhang, "Effect of lycopene supplementation on oxidative stress: an exploratory systematic review and meta-analysis of randomized controlled trials," *Journal of medicinal food*, vol. 16, no. 5, pp. 361–374, 2013, publisher: Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
- [41] Z. Khan, P. Bhadouria, and P. Bisen, "Nutritional and therapeutic potential of Spirulina," *Current pharmaceutical biotechnology*, vol. 6, no. 5, pp. 373–379, 2005, publisher: Bentham Science Publishers.
- [42] A. Sarubin-Fragakis, *The health professional's guide to popular dietary supplements*. American Dietetic Associati, 2007.
- [43] P. Parikh, U. Mani, and U. Iyer, "Role of Spirulina in the control of glycemia and lipidemia in type 2 diabetes mellitus," *Journal of Medicinal Food*, vol. 4, no. 4, pp. 193–199, 2001, publisher: Mary Ann Liebert, Inc.
- [44] E. H. Lee, J.-E. Park, Y.-J. Choi, K.-B. Huh, and W.-Y. Kim, "A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients," *Nutrition Research and Practice*, vol. 2, no. 4, pp. 295–300, 2008, publisher: The Korean Nutrition Society and The Korean Society of Community Nutrition.
- [45] P. V. Torres-Duran, A. Ferreira-Hermosillo, and M. A. Juarez-Oropeza, "Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report," *Lipids in Health and Disease*, vol. 6, no. 1, pp. 1–8, 2007, publisher: BioMed Central.
- [46] E. E. Mazokopakis, M. G. Papadomanolaki, A. A. Fusteris, D. A. Kotsiris, I. M. Lampadakis, and E. S. Ganotakis, "The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study," *Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology*, vol. 27, no. 4, p. 387, 2014, publisher: The Hellenic Society of Gastroenterology.
- [47] M.-C. Serban, A. Sahebkar, S. Dragan, G. Stoichescu-Hogea, S. Ursoniu, F. Andrica, and M. Banach, "A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations," *Clinical Nutrition*, vol. 35, no. 4, pp. 842–851, 2016, publisher: Elsevier.
- [48] W. Wongcharoen and A. Phrommintikul, "The protective role of curcumin in cardiovascular diseases," *International journal of cardiology*, vol. 133, no. 2, pp. 145–151, 2009, publisher: Elsevier.
- [49] Y. Panahi, Y. Ahmadi, M. Teymouri, T. P. Johnston, and A. Sahebkar, "Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms," *Journal of cellular physiology*, vol. 233, no. 1, pp. 141–152, 2018, publisher: Wiley Online Library.
- [50] S. Ganjali, A. Sahebkar, E. Mahdipour, K. Jamialahmadi, S. Torabi, S. Akhlaghi, G. Ferns, S. M. R. Parizadeh, and M. Ghayour-Mobarhan, "Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial," *The Scientific World Journal*, vol. 2014, 2014, publisher: Hindawi.
- [51] Y. Panahi, M. S. Hosseini, N. Khalili, E. Naimi, L. E. Simental-Mendia, M. Majeed, and A. Sahebkar, "Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial," *Biomedicine & pharmacotherapy*, vol. 82, pp. 578–582, 2016, publisher: Elsevier.
- [52] Y. Panahi, N. Khalili, M. S. Hosseini, M. Abbasiazari, and A. Sahebkar, "Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial," *Complementary therapies in medicine*, vol. 22, no. 5, pp. 851–857, 2014, publisher: Elsevier.
- [53] S. Ganjali, C. N. Blesso, M. Banach, M. Pirro, M. Majeed, and A. Sahebkar, "Effects of curcumin on HDL functionality," *Pharmacological research*, vol. 119, pp. 208–218, 2017, publisher: Elsevier.
- [54] N. Guo, F. Chen, J. Zhou, Y. Fang, H. Li, Y. Luo, and Y. Zhang, "Curcumin attenuates rapamycin-induced cell injury of vascular endothelial cells," *Journal of cardiovascular pharmacology*, vol. 66, no. 4, pp. 338–346, 2015, publisher: LWW.
- [55] M. S. Karimian, M. Pirro, T. P. Johnston, M. Majeed, and A. Sahebkar, "Curcumin and endothelial function: evidence and mechanisms of protective effects," *Current pharmaceutical design*, vol. 23, no. 17, pp. 2462–2473, 2017, publisher: Bentham Science Publishers.
- [56] G. Appendino, G. Belcaro, U. Cornelli, R. Luzzi, S. Togni, M. Dugall, M. Cesarone, B. Feragalli, E. Ippolito, and B. Errichi, "Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study," *Panminerva Med*, vol. 53, no. 3 Suppl 1, pp. 43–49, 2011.
- [57] V. Karuppagounder, S. Arumugam, V. V. Giridharan, R. Sreedhar, R. J. Bose, J. Vanama, S. S. Palaniyandi, T. Konishi, K. Watanabe, and R. A. Thandavarayan, "Tiny molecule, big power: multi-target approach for curcumin in diabetic cardiomyopathy," *Nutrition*, vol. 34, pp. 47–54, 2017, publisher: Elsevier.
- [58] P. M. Giovannetti, K. K. Carroll, and B. M. Wolfe, "Constancy of fasting serum cholesterol of healthy young women upon substitution of soy protein isolate for meat and dairy protein in medium and low fat diets," *Nutrition Research*, vol. 6, no. 6, pp. 609–618, 1986, publisher: Elsevier.
- [59] D. J. Jenkins, T. M. Wolever, G. Spiller, G. Buckley, Y. Lam, A. L. Jenkins, and R. G. Josse, "Hypocholesterolemic effect of vegetable protein in a hypocaloric diet," *Atherosclerosis*, vol. 78, no. 2-3, pp. 99–107, 1989, publisher: Elsevier.
- [60] O. Bosello, L. Cominacini, I. Zocca, U. Garbin, R. Compri, A. Davoli, and L. Brunetti, "Short-and long-term effects of hypocaloric diets containing proteins of different sources on plasma lipids and apoproteins of obese subjects," *Annals of nutrition and metabolism*, vol. 32, no. 4, pp. 206–214, 1988, publisher: Karger Publishers.
- [61] F. M. Sacks, J. L. Breslow, P. G. Wood, and E. H. Kass, "Lack of an effect of dairy protein (casein) and soy protein on plasma cholesterol of strict vegetarians. An experiment and a critical review," *Journal of lipid research*, vol. 24, no. 8, pp. 1012–1020, 1983, publisher: Elsevier.
- [62] W. W. Wong, E. Smith, J. E. Stuff, D. L. Hachey, W. C. Heird, and H. J. Pownell, "Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men," *The American journal of clinical nutrition*, vol. 68, no. 6, pp. 1385S–1389S, 1998, publisher: Oxford University Press.
- [63] J. A. Baum, H. Teng, J. W. Erdman Jr, R. M. Weigel, B. P. Klein, V. W. Persky, S. Freels, P. Surya, R. M. Bakhit, and E. Ramos, "Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women," *The American journal of clinical nutrition*, vol. 68, no. 3, pp. 545–551, 1998, publisher: Oxford University Press.

- [64] E. M. Kurowska, J. Jordon, J. D. Spence, and S. Wetmore, "Effects of substituting dietary soybean protein and oil for milk protein and fat in subjects with hypercholesterolemia," *Clinical and investigative medicine*, vol. 20, no. 3, p. 162, 1997, publisher: Canadian Society for Clinical Investigation.
- [65] G. Fonda, R. Pranata, and H. Deka, "Role of Omega-3 Fatty Acids in Dyslipidemia and Cardiovascular Diseases," *Indonesian Journal of Cardiology*, pp. 213–22, 2016.
- [66] C. Sharma, "Phyto-Pharmacological Aspects of Ethnomedicinal Plants Found In Himalayan Region," *Der Pharma Chemica*, 2021.
- [67] D. Mozaffarian and J. H. Wu, "Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events," *Journal of the American College of Cardiology*, vol. 58, no. 20, pp. 2047–2067, 2011, publisher: American College of Cardiology Foundation Washington, DC.
- [68] Y. Adkins and D. S. Kelley, "Mechanisms underlying the cardio-protective effects of omega-3 polyunsaturated fatty acids," *The Journal of nutritional biochemistry*, vol. 21, no. 9, pp. 781–792, 2010, publisher: Elsevier.
- [69] A. D. Toft, M. Thorn, K. Ostrowski, S. Asp, K. Møller, S. Iversen, C. Hermann, S. R. Søndergaard, and B. K. Pedersen, "N-3 polyunsaturated fatty acids do not affect cytokine response to strenuous exercise," *Journal of applied physiology*, vol. 89, no. 6, pp. 2401–2406, 2000, publisher: American Physiological Society Bethesda, MD.
- [70] M. Massaro, E. Scoditti, M. A. Carluccio, and R. De Caterina, "Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease," *Prostaglandins, Leukotrienes and Essential Fatty Acids*, vol. 79, no. 3-5, pp. 109–115, 2008, publisher: Elsevier.
- [71] M. G. Cohen, J. S. Rossi, J. Garbarino, R. Bowling, A. A. Motsinger-Reif, C. Schuler, A. G. Dupont, and D. Gabriel, "Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel," *Thrombosis research*, vol. 128, no. 4, pp. 335–340, 2011, publisher: Elsevier.
- [72] T. A. Jacobson, S. B. Glickstein, J. D. Rowe, and P. N. Soni, "Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review," *Journal of clinical lipidology*, vol. 6, no. 1, pp. 5–18, 2012, publisher: Elsevier.
- [73] D. Kromhout, E. J. Giltay, and J. M. Geleijnse, "n-3 Fatty acids and cardiovascular events after myocardial infarction," *New England Journal of Medicine*, vol. 363, no. 21, pp. 2015–2026, 2010, publisher: Mass Medical Soc.
- [74] S. Kotwal, M. Jun, D. Sullivan, V. Perkovic, and B. Neal, "Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis," *Circulation: Cardiovascular Quality and Outcomes*, vol. 5, no. 6, pp. 808–818, 2012, publisher: Am Heart Assoc.
- [75] A. Martino, E. Goanta, R. Magnano, S. Bencivenga, and L. Pezzi, "Diets and heart disease. Myths and reality," *J Nutrition Health Food Sci*, vol. 4, no. 1, pp. 1–10, 2016.